{"id":"https://openalex.org/W2985384872","doi":"https://doi.org/10.1093/neuonc/noz175.613","title":"PATH-17. HYPERPROGRESSIVE DISEASE IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMAS TREATED WITH IMMUNE CHECKPOINT INHIBITORS OR CYTOTOXIC THERAPIES","display_name":"PATH-17. HYPERPROGRESSIVE DISEASE IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMAS TREATED WITH IMMUNE CHECKPOINT INHIBITORS OR CYTOTOXIC THERAPIES","publication_year":2019,"publication_date":"2019-11-01","ids":{"openalex":"https://openalex.org/W2985384872","doi":"https://doi.org/10.1093/neuonc/noz175.613","mag":"2985384872"},"language":"en","primary_location":{"id":"doi:10.1093/neuonc/noz175.613","doi":"https://doi.org/10.1093/neuonc/noz175.613","is_oa":false,"landing_page_url":"https://doi.org/10.1093/neuonc/noz175.613","pdf_url":null,"source":{"id":"https://openalex.org/S106908163","display_name":"Neuro-Oncology","issn_l":"1522-8517","issn":["1522-8517","1523-5866"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuro-Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6847436","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Laura Donovan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2799503643","display_name":"Columbia University Irving Medical Center","ror":"https://ror.org/01esghr10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799503643"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Laura Donovan","raw_affiliation_strings":["Columbia University Irving Medical Center, New York, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Columbia University Irving Medical Center, New York, NY, USA","institution_ids":["https://openalex.org/I2799503643"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011587106","display_name":"Samuel Gedailovich","orcid":"https://orcid.org/0000-0003-3257-4917","observed_orcids":["https://orcid.org/0000-0003-3257-4917"]},"institutions":[{"id":"https://openalex.org/I78577930","display_name":"Columbia University","ror":"https://ror.org/00hj8s172","country_code":"US","type":"education","lineage":["https://openalex.org/I78577930"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Samuel Gedailovich","raw_affiliation_strings":["Columbia University, New York, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Columbia University, New York, NY, USA","institution_ids":["https://openalex.org/I78577930"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080062627","display_name":"Adela Joanta-Gomez","orcid":"https://orcid.org/0000-0001-5109-1326","observed_orcids":["https://orcid.org/0000-0001-5109-1326"]},"institutions":[{"id":"https://openalex.org/I2799503643","display_name":"Columbia University Irving Medical Center","ror":"https://ror.org/01esghr10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799503643"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Adela Joanta-Gomez","raw_affiliation_strings":["Columbia University Irving Medical Center, New York, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Columbia University Irving Medical Center, New York, NY, USA","institution_ids":["https://openalex.org/I2799503643"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057541817","display_name":"Andrew B. Lassman","orcid":"https://orcid.org/0000-0001-7386-9928","observed_orcids":["https://orcid.org/0000-0001-7386-9928"]},"institutions":[{"id":"https://openalex.org/I2799503643","display_name":"Columbia University Irving Medical Center","ror":"https://ror.org/01esghr10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799503643"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew Lassman","raw_affiliation_strings":["Columbia University Irving Medical Center, New York, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Columbia University Irving Medical Center, New York, NY, USA","institution_ids":["https://openalex.org/I2799503643"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5087754052","display_name":"FABIO MASSAITI IWAMOTO","orcid":"https://orcid.org/0000-0003-1397-9927","observed_orcids":["https://orcid.org/0000-0003-1397-9927"]},"institutions":[{"id":"https://openalex.org/I1340179700","display_name":"NewYork\u2013Presbyterian Hospital","ror":"https://ror.org/03gzbrs57","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1340179700"]},{"id":"https://openalex.org/I2799503643","display_name":"Columbia University Irving Medical Center","ror":"https://ror.org/01esghr10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799503643"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Fabio Iwamoto","raw_affiliation_strings":["New York Presbyterian Hospital-Columbia University Irving Medical Center, New York, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"New York Presbyterian Hospital-Columbia University Irving Medical Center, New York, NY, USA","institution_ids":["https://openalex.org/I1340179700","https://openalex.org/I2799503643"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5132,"currency":"USD","value_usd":5132},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"21","issue":"Supplement_6","first_page":"vi146","last_page":"vi146"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.8560000061988831,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.8560000061988831,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.1412000060081482,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11829","display_name":"Mathematical Biology Tumor Growth","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2611","display_name":"Modeling and Simulation"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/hyperprogressive-disease","display_name":"hyperprogressive disease","score":0.9860000014305115},{"id":"https://openalex.org/keywords/recurrent-high-grade-glioma","display_name":"recurrent high-grade glioma","score":0.8579999804496765},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.8450000286102295},{"id":"https://openalex.org/keywords/glioblastoma","display_name":"glioblastoma","score":0.8149999976158142},{"id":"https://openalex.org/keywords/tumor-growth-rate","display_name":"tumor growth rate","score":0.9369999766349792},{"id":"https://openalex.org/keywords/cytotoxic-therapy","display_name":"cytotoxic therapy","score":0.8059999942779541},{"id":"https://openalex.org/keywords/pten-mutation","display_name":"PTEN mutation","score":0.753000020980835},{"id":"https://openalex.org/keywords/egfr-alterations","display_name":"EGFR alterations","score":0.7979999780654907},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.5210000276565552},{"id":"https://openalex.org/keywords/next-generation-sequencing","display_name":"next-generation sequencing","score":0.515999972820282}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8422344923019409},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.7792584896087646},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6720032095909119},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5415076017379761},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.5323700308799744},{"id":"https://openalex.org/C2778227246","wikidata":"https://www.wikidata.org/wiki/Q1365309","display_name":"Glioma","level":2,"score":0.47237470746040344},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.4212602376937866},{"id":"https://openalex.org/C2779256057","wikidata":"https://www.wikidata.org/wiki/Q16909647","display_name":"Tumor progression","level":3,"score":0.4140131175518036},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.36397624015808105},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2679557800292969},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.25927579402923584},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2488667070865631},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.1329345405101776}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1093/neuonc/noz175.613","doi":"https://doi.org/10.1093/neuonc/noz175.613","is_oa":false,"landing_page_url":"https://doi.org/10.1093/neuonc/noz175.613","pdf_url":null,"source":{"id":"https://openalex.org/S106908163","display_name":"Neuro-Oncology","issn_l":"1522-8517","issn":["1522-8517","1523-5866"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuro-Oncology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:6847436","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6847436","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuro Oncol","raw_type":"Text"}],"best_oa_location":{"id":"pmh:oai:pubmedcentral.nih.gov:6847436","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6847436","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neuro Oncol","raw_type":"Text"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2947660016","https://openalex.org/W4407260487","https://openalex.org/W2896019378","https://openalex.org/W4402194006","https://openalex.org/W2899974395","https://openalex.org/W3029879800","https://openalex.org/W2891652640","https://openalex.org/W4282924171","https://openalex.org/W2947391881","https://openalex.org/W2889950294"],"abstract_inverted_index":{"Abstract":[0],"BACKGROUND":[1],"Hyperprogressive":[2],"disease":[3],"(HPD),":[4],"defined":[5],"as":[6],"a":[7,77,150,170],"\u2265":[8],"2-fold":[9],"increase":[10],"in":[11,29,47,130,136,183,194,201,207,213,228,233,243,247,265,274,293],"tumor":[12],"growth":[13],"rate":[14,44],"(TGR)":[15],"compared":[16,57,75,187],"to":[17,58,76,94,188,284],"baseline":[18],"following":[19],"initiation":[20],"of":[21,45,152,172,177,231,295],"immune":[22],"checkpoint":[23],"inhibitors":[24],"(ICI),":[25],"has":[26],"been":[27],"described":[28],"solid":[30],"tumors":[31],"but":[32,289],"is":[33,272],"not":[34,255],"well":[35],"explored":[36],"high":[37],"grade":[38],"gliomas":[39],"(HGG).":[40],"We":[41],"investigated":[42],"the":[43,131,137,184,202],"HPD":[46,102,182,242,258,266,271],"HGG":[48,67,277],"patients":[49,115,124,129,178,195,214,232,275,296],"receiving":[50,68,79,125,218,297],"ICIs":[51,69,126],"for":[52,70,181,220],"first":[53,83,159],"or":[54,72,86,89],"second":[55],"recurrence":[56,74,222],"those":[59,285],"treated":[60,157,278],"with":[61,66,99,196,215,241,257,276,279,286],"non-immunotherapy":[62],"agents.":[63],"METHODS":[64],"Patients":[65],"1st":[71,221],"2nd":[73],"controls":[78,190],"other":[80,287,298],"therapies":[81],"at":[82,158,281],"progression.":[84],"Prior":[85],"concurrent":[87],"bevacizumab":[88],"anti-VEGFR":[90],"were":[91,134,156,163,254,262],"exclusionary":[92],"due":[93],"pseudoresponse":[95],"and":[96,110,127,146,167,245,251],"decreased":[97],"enhancement":[98],"these":[100],"drugs.":[101],"was":[103,199,224,290],"calculated":[104],"by":[105],"comparing":[106],"TGR":[107],"immediately":[108],"before":[109],"after":[111],"treatment.":[112],"RESULTS":[113],"49":[114],"met":[116,179],"inclusion":[117],"criteria":[118,180],"(27":[119],"ICI,":[120],"25":[121],"control).":[122,248],"25/27":[123],"20/22":[128],"control":[132],"group":[133,141,186,204],"evaluable":[135],"analysis.":[138],"The":[139],"ICI":[140,185,203,219,244,280],"included":[142],"60%":[143],"men":[144],"(15/25)":[145],"80%":[147,164],"(20/25)":[148],"had":[149,169,236],"diagnosis":[151,171],"primary":[153,173,197,216],"GBM.":[154,174],"68%":[155],"progression":[160,212],"(17/25).":[161],"Controls":[162],"male":[165],"(16/20)":[166],"all":[168],"28%":[175],"(7/25)":[176],"4/20":[189],"(20%).":[191],"Median":[192,209],"OS":[193],"GBM":[198,217],"26mo":[200],"vs.":[205,226,268],"15.9mo":[206],"controls.":[208,229],"survival":[210],"past":[211],"(13/25)":[223],"12mo":[225],"10.6mo":[227],"40%":[230],"both":[234],"groups":[235],"next":[237],"generation":[238],"sequencing":[239],"(5/7":[240],"2/4":[246],"EGFR":[249],"alterations":[250],"MDM2/4":[252],"amplifications":[253],"associated":[256],"whereas":[259],"PTEN":[260],"mutations":[261],"more":[263],"common":[264],"(71%":[267],"33.3%).":[269],"CONCLUSION":[270],"observed":[273,292],"comparable":[282],"rates":[283],"cancers,":[288],"also":[291],"20%":[294],"therapies.":[299]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2019-11-22T00:00:00"}